AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Agenus to Host Stakeholder Webcast on Immuno-Oncology Advancements on August 27, 2025
ByAinvest
Tuesday, Aug 26, 2025 5:45 pm ET1min read
Agenus will host a virtual Stakeholder Briefing on August 27 to discuss recent immuno-oncology advancements, including BOT/BAL clinical data and partnership updates. The event will cover CRC studies, BATTMAN Phase 3 study, and MiNK Therapeutics, with a live Q&A session featuring company leaders and experts. The briefing will provide insights into Agenus' work in cancer immunotherapy, leveraging Botensilimab and Balstilimab.
Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company, will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event aims to provide insights into recent advancements in immuno-oncology, including clinical data from the BOT/BAL program and updates on partnerships. The briefing will cover various topics, including colorectal cancer (CRC) studies, the Phase 3 BATTMAN study, and collaborations with MiNK Therapeutics, with a live Q&A session featuring company leaders and experts.Key highlights of the briefing include a strategic and financial overview, updates on the Zydus partnership, and patient needs fueling interest in CRC studies. The agenda will also cover recent clinical data from the botensilimab (BOT) and balstilimab (BAL) program, as well as an overview of the Phase 3 BATTMAN study in metastatic CRC. Additionally, the session will feature a spotlight on MiNK Therapeutics and upcoming milestones across Agenus' portfolio.
Speakers at the event will include Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus; Richard M. Goldberg, MD, Chief Development Officer; Jennifer Buell, PhD, CEO of MiNK Therapeutics; Nicholas C. DeVito, MD, Assistant Professor of Medical Oncology at Duke University; and Chris O'Callaghan, DVM, MSc, PhD, Senior Investigator at Canadian Cancer Trials Group (CCTG).
The virtual briefing will be accessible via the link [https://riverside.fm/studio/agenus-presentation](https://riverside.fm/studio/agenus-presentation), with no pre-registration required. The event is open to all stakeholders and investors interested in Agenus' work in cancer immunotherapy and its portfolio of immunological agents.
References:
[1] https://www.businesswire.com/news/home/20250826512064/en/Update-Agenus-Aug-27-Stakeholder-WebcastTransformative-IO-Updates-BOTBAL-Data-BATTMAN-Preview-Zydus-Partnership-Momentum-and-MiNK-Spotlight
[2] https://www.biospace.com/press-releases/agenus-to-unveil-bot-bal-strategic-advancements-key-milestones-and-future-outlook-in-virtual-stakeholder-briefing-on-august-27-2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet